Work

Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III ALEX trial.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.9053

Authors: Rafal Dziadziuszko, Solange Peters, Tony S. K. Mok, D. Ross Camidge, Johannes Noé, Malgorzata Nowicka, Walter Bordogna, Peter N. Morcos, Vlatka Smoljanovic, Alice Tsang Shaw

Institutions: Gdańsk Medical University, Centre Hospitalier Universitaire Vaudois, Prince of Wales Hospital, University of Colorado Cancer Center, Roche (Switzerland), Harvard University, Massachusetts General Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2946961640

Cites:

Cited by: 2

Related to: 10